Diagnostic heterogeneity in orthopaedic oncology makes standardized recommendations regarding anticoagulation difficult

Patients with cancer have a high incidence of venous thromboembolism (VTE). It is estimated that fifteen percent of patients with carcinoma develop VTE (1). Sarcoma patients have a similar incidence of VTE (2). Patients undergoing major orthopedic procedures are also at increased risk for developing VTE.